Compare Johnson & Johnson (JNJ) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Johnson & Johnson trades at $248.27 (market cap $609.12B), while GraniteShares 2x Long NVDA Daily ETF trades at $30.99. The key difference: Johnson & Johnson pays a 2.12% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | NVDL | |
|---|---|---|
Market Cap | $609.12B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $43.02 |
52-Week Low | $164.36 | $21.76 |
Enterprise Value | $642.06B | — |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.51 with a 0.76% daily gain. The technical outlook is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, including a 12% single-day drop on June 5, 2026, and a 67% decline in early 2025, underscoring the risks of daily leverage reset mechanics.
The outlook for NVDL is heavily tied to NVIDIA's performance and AI sector momentum. While the ETF has delivered strong returns year-to-date (up 12.66% as of June 8, 2026), its leveraged structure amplifies both gains and losses. Key risks include NVIDIA's earnings volatility, broader semiconductor market swings, and the compounding effect of daily resets during downtrends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
